Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2015, Article ID 704124, 14 pages
http://dx.doi.org/10.1155/2015/704124
Review Article

Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin

1Department of Obstetrics and Gynecology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Herestraat 49, Box 7003, 3000 Leuven, Belgium
2Gynecologic Oncology Unit, Fondazione IRCCS National Cancer Institute, Via Venezian 1, 20133 Milan, Italy
3Department of Gynecology and Obstetrics, University Hospital Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany
4Department of Medical Oncology, La Timone University Hospital, 264 rue Saint Pierre, 13385 Marseille, France
5Département de Medecine, Institut Gustave-Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France

Received 19 February 2015; Accepted 28 April 2015

Academic Editor: Chandrajit Premanand Raut

Copyright © 2015 Frédéric Amant et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. D'Angelo and J. Prat, “Uterine sarcomas: a review,” Gynecologic Oncology, vol. 116, no. 1, pp. 131–139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote, “Endometrial cancer,” The Lancet, vol. 366, no. 9484, pp. 491–505, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. R. Toro, L. B. Travis, J. W. Hongyu, K. Zhu, C. D. M. Fletcher, and S. S. Devesa, “Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978-2001: an analysis of 26,758 cases,” International Journal of Cancer, vol. 119, no. 12, pp. 2922–2930, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. E. Rha, J. Y. Byun, S. E. Jung et al., “CT and MRI of uterine sarcomas and their mimickers,” American Journal of Roentgenology, vol. 181, no. 5, pp. 1369–1374, 2003. View at Google Scholar
  5. D. S. Kapp, J. Y. Shin, and J. K. Chan, “Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy,” Cancer, vol. 112, no. 4, pp. 820–830, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Zivanovic, L. M. Jacks, A. Iasonos et al., “A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma,” Cancer, vol. 118, no. 3, pp. 660–669, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Iasonos, E. Z. Keung, O. Zivanovic et al., “External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma,” Cancer, vol. 119, no. 10, pp. 1816–1822, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. J.-Y. Park, D.-Y. Kim, D.-S. Suh et al., “Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989–2007,” Journal of Cancer Research and Clinical Oncology, vol. 134, no. 12, pp. 1277–1287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-Y. Park, S.-K. Park, D.-Y. Kim et al., “The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma,” Gynecologic Oncology, vol. 122, no. 2, pp. 255–259, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. R. O'Cearbhaill and M. L. Hensley, “Optimal management of uterine leiomyosarcoma,” Expert Review of Anticancer Therapy, vol. 10, no. 2, pp. 153–169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. P. Shah, C. S. Bryant, S. Kumar, R. Ali-Fehmi, J. M. Malone, and R. T. Morris, “Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma,” Obstetrics and Gynecology, vol. 112, no. 5, pp. 1102–1108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. K. Chan, N. M. Kawar, J. Y. Shin et al., “Endometrial stromal sarcoma: a population-based analysis,” British Journal of Cancer, vol. 99, no. 8, pp. 1210–1215, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. M. Leitao, Y. Sonoda, M. F. Brennan, R. R. Barakat, and D. S. Chi, “Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus,” Gynecologic Oncology, vol. 91, no. 1, pp. 209–212, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. R. L. Giuntoli II, D. S. Metzinger, C. S. DiMarco et al., “Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy,” Gynecologic Oncology, vol. 89, no. 3, pp. 460–469, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. M. M. Leitao, M. F. Brennan, M. Hensley et al., “Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma,” Gynecologic Oncology, vol. 87, no. 3, pp. 287–294, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. S. H. Blackmon, N. Shah, J. A. Roth et al., “Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival,” Annals of Thoracic Surgery, vol. 88, no. 3, pp. 877–885, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. G. Casson, J. B. Putnam, G. Natarajan et al., “Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma,” Cancer, vol. 69, no. 3, pp. 662–668, 1992. View at Google Scholar · View at Scopus
  18. D. Gossot, C. Radu, P. Girard et al., “Resection of pulmonary metastases from sarcoma: can some patients benefit from a less invasive approach?” Annals of Thoracic Surgery, vol. 87, no. 1, pp. 238–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Rehders, S. B. Hosch, P. Scheunemann, N. H. Stoecklein, W. T. Knoefel, and M. Peiper, “Benefit of surgical treatment of lung metastasis in soft tissue sarcoma,” Archives of Surgery, vol. 142, no. 1, pp. 70–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. N. B. Hornback, G. Omura, and F. J. Major, “Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma,” International Journal of Radiation, Oncology, Biology, Physics, vol. 12, no. 12, pp. 2127–2130, 1986. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Sampath, T. E. Schultheiss, J. K. Ryu, and J. Y. Wong, “The role of adjuvant radiation in uterine sarcomas,” International Journal of Radiation Oncology, Biology, Physics, vol. 76, no. 3, pp. 728–734, 2010. View at Publisher · View at Google Scholar
  22. N. S. Reed, C. Mangioni, H. Malmström et al., “Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874),” European Journal of Cancer, vol. 44, no. 6, pp. 808–818, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Ricci, R. L. Giuntoli II, E. Eisenhauer et al., “Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?” Gynecologic Oncology, vol. 131, no. 3, pp. 629–633, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. S. M. Schuetze and M. E. Ray, “Adjuvant therapy for soft tissue sarcoma,” Journal of the National Comprehensive Cancer Network, vol. 3, no. 2, pp. 207–213, 2005. View at Google Scholar
  25. G. A. Omura, J. A. Blessing, F. Major et al., “A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 3, no. 9, pp. 1240–1245, 1985. View at Google Scholar · View at Scopus
  26. “Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC),” Cochrane Database of Systematic Reviews, no. 2, Article ID CD001419, 2000.
  27. P. Pautier, A. Floquet, L. Gladieff et al., “A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group,” Annals of Oncology, vol. 24, no. 4, pp. 1099–1104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. P. J. Woll, P. Reichardt, A. le Cesne et al., “Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial,” The Lancet Oncology, vol. 13, no. 10, pp. 1045–1054, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. T. A. Dinh, E. A. Oliva, A. F. Fuller Jr., H. Lee, and A. Goodman, “The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990–1999) at the Massachusetts General Hospital,” Gynecologic Oncology, vol. 92, no. 2, pp. 648–652, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. O. Zivanovic, M. M. Leitao, A. Iasonos et al., “Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2066–2072, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Kanjeekal, A. Chambers, M. Fung Kee Fung, and S. Verma, “Systemic therapy for advanced uterine sarcoma: a systematic review of the literature,” Gynecologic Oncology, vol. 97, no. 2, pp. 624–637, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Sutton, J. A. Blessing, and J. H. Malfetano, “Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 62, no. 2, pp. 226–229, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Sleijfer, C. Seynaeve, and J. Verweij, “Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care,” Oncologist, vol. 10, no. 10, pp. 833–841, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. H. B. Muss, B. Bundy, P. J. DiSaia et al., “Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide. (A phase III trial of the gynecologic oncology group),” Cancer, vol. 55, no. 8, pp. 1648–1653, 1985. View at Publisher · View at Google Scholar · View at Scopus
  35. G. A. Omura, F. J. Major, J. A. Blessing et al., “A randomized study of Adriamycin with and without dimethyl triazeoimidazole carboxamide in advanced uterine sarcomas,” Cancer, vol. 52, no. 4, pp. 626–632, 1983. View at Publisher · View at Google Scholar · View at Scopus
  36. G. P. Sutton, J. A. Blessing, R. J. Barrett, and R. McGehee, “Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study,” The American Journal of Obstetrics and Gynecology, vol. 166, no. 2, pp. 556–559, 1992. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Leyvraz, M. Zweifel, G. Jundt et al., “Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas,” Annals of Oncology, vol. 17, no. 4, pp. 646–651, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Maurel, A. López-Pousa, R. De Las Peñas et al., “Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas,” Journal of Clinical Oncology, vol. 27, no. 11, pp. 1893–1898, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Judson, J. Verweij, H. Gelderblom et al., “Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial,” The Lancet Oncology, vol. 15, no. 4, pp. 415–423, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Y. Look, A. Sandler, J. A. Blessing, J. A. Lucci III, and P. G. Rose, “Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study,” Gynecologic Oncology, vol. 92, no. 2, pp. 644–647, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. M. L. Hensley, “Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas,” Current Opinion in Oncology, vol. 22, no. 4, pp. 356–361, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. L. Hensley, J. A. Blessing, K. DeGeest, O. Abulafia, P. G. Rose, and H. D. Homesley, “Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study,” Gynecologic Oncology, vol. 109, no. 3, pp. 323–328, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. M. L. Hensley, J. A. Blessing, R. Mannel, and P. G. Rose, “Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial,” Gynecologic Oncology, vol. 109, no. 3, pp. 329–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. M. L. Hensley, R. Maki, E. Venkatraman et al., “Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial,” Journal of Clinical Oncology, vol. 20, no. 12, pp. 2824–2831, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. R. G. Maki, J. K. Wathen, S. R. Patel et al., “Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2755–2763, 2007. View at Publisher · View at Google Scholar
  46. J.-O. Bay, I. Ray-Coquard, J. Fayette et al., “Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis,” International Journal of Cancer, vol. 119, no. 3, pp. 706–711, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Pautier, A. Floquet, N. Penel et al., “Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a fédération nationale des centres de lutte contre le cancer (FNCLCC) french sarcoma group study (TAXOGEM study),” Oncologist, vol. 17, no. 9, pp. 1213–1220, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Duffaud, P. Pautier, B. Bui et al., “A pooled analysis of the final results of the two randomized phase II studies comparing gemcitabine (G) vs. gemcitabine + docetaxel (G+D) in patients (pts) with metastatic/relapsed leiomyosarcoma (LMS),” Annals of Oncology, vol. 21, supplement 8, pp. viii408–viii416, 2010, Proceedings of the 35th ESMO Congress, abstract 1345O, Milan, Italy, October 2010. View at Publisher · View at Google Scholar
  49. B. J. Monk, J. A. Blessing, D. G. Street, C. Y. Muller, J. J. Burke, and M. L. Hensley, “A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study,” Gynecologic Oncology, vol. 124, no. 1, pp. 48–52, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Pautier, A. Floquet, D. Cupissol et al., “LMS-02: a phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): first results in patients with u-LMS,” Journal of Clinical Oncology, vol. 31, supplement, abstract 10505, 2013. View at Google Scholar
  51. I. R. Judson, J. Blay, S. P. Chawla et al., “Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): results of a pooled analysis of five single-agent phase II studies using the recommended dose,” Journal of Clinical Oncology, vol. 28, no. 15s, supplement, abstract 10028, 2010. View at Google Scholar
  52. R. Sanfilippo, F. Grosso, R. L. Jones et al., “Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers,” Gynecologic Oncology, vol. 123, no. 3, pp. 553–556, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. A. le Cesne, J. Y. Blay, I. Judson et al., “Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 576–584, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Yovine, M. Riofrio, J. Y. Blay et al., “Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 890–899, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Garcia-Carbonero, J. G. Supko, R. G. Maki et al., “Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5484–5492, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Garcia-Carbonero, J. G. Supko, J. Manola et al., “Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy,” Journal of Clinical Oncology, vol. 22, no. 8, pp. 1480–1490, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. G. D. Demetri, S. P. Chawla, M. von Mehren et al., “Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules,” Journal of Clinical Oncology, vol. 27, no. 25, pp. 4188–4196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Harter, U. Canzler, H. Lueck et al., “Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: a phase II trial of the AGO study group,” Journal of Clinical Oncology, vol. 29, supplement, abstract 5093, 2011. View at Google Scholar
  59. M. S. Boyar, M. Hesdorffer, M. L. Keohan, Z. Jin, and R. N. Taub, “Phase II study of temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma,” Sarcoma, vol. 2008, Article ID 412503, 6 pages, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Anderson and C. Aghajanian, “Temozolomide in uterine leiomyosarcomas,” Gynecologic Oncology, vol. 98, no. 1, pp. 99–103, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. S. M. Talbot, M. L. Keohan, M. Hesdorffer et al., “A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma,” Cancer, vol. 98, no. 9, pp. 1942–1946, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. D. S. Miller, J. A. Blessing, L. C. Kilgore, R. Mannel, and L. van Le, “Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group study,” The American Journal of Clinical Oncology, vol. 23, no. 4, pp. 355–357, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. D. G. Gallup, J. A. Blessing, W. Andersen, and M. A. Morgan, “Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study,” Gynecologic Oncology, vol. 89, no. 1, pp. 48–51, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. J. T. Thigpen, J. A. Blessing, and G. D. Wilbanks, “Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A Phase II trial of the Gynecologic Oncology Group,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 9, no. 1, pp. 18–20, 1986. View at Google Scholar · View at Scopus
  65. W. T. A. van der Graaf, J.-Y. Blay, S. P. Chawla et al., “Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial,” The Lancet, vol. 379, no. 9829, pp. 1879–1886, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. M. L. Hensley, A. Miller, D. O'Malley et al., “A randomized phase III trial of gemcitabine+docetaxel+bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma (uLMS): a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 133, supplement 1, p. 3, 2014. View at Publisher · View at Google Scholar
  67. C. F. Verschraegen, H. Arias-pulido, S.-J. Lee et al., “Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the axtell regimen,” Annals of Oncology, vol. 23, no. 3, pp. 785–790, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. D. R. D'Adamo, S. E. Anderson, K. Albritton et al., “Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 7135–7142, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. R. G. Maki, D. R. D'Adamo, M. L. Keohan et al., “Phase II study of sorafenib in patients with metastatic or recurrent sarcomas,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3133–3140, 2009. View at Google Scholar
  70. M. L. Hensley, M. W. Sill, D. R. Scribner Jr. et al., “Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study,” Gynecologic Oncology, vol. 115, no. 3, pp. 460–465, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. B. M. Seddon and R. Davda, “Uterine sarcomas—recent progress and future challenges,” European Journal of Radiology, vol. 78, no. 1, pp. 30–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. M. M. Leitao Jr., M. L. Hensley, R. R. Barakat et al., “Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma,” Gynecologic Oncology, vol. 124, no. 3, pp. 558–562, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Mittal and R. I. Demopoulos, “MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors,” Human Pathology, vol. 32, no. 9, pp. 984–987, 2001. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. L. Zhai, Y. Kobayashi, A. Mori et al., “Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas,” International Journal of Gynecological Pathology, vol. 18, no. 1, pp. 20–28, 1999. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. J. Ioffe, A. J. Li, C. S. Walsh et al., “Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles,” Gynecologic Oncology, vol. 115, no. 3, pp. 466–471, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. R. O'Cearbhaill, Q. Zhou, A. Iasonos et al., “Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors,” Gynecologic Oncology, vol. 116, no. 3, pp. 424–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. M. R. Raspollini, G. Amunni, A. Villanucci et al., “Estrogen and progesterone receptors expression in uterine malignant smooth muscle tumors: correlation with clinical outcome,” Journal of Chemotherapy, vol. 15, no. 6, pp. 596–602, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. F. Amant, A. Coosemans, M. Debiec-Rychter, D. Timmerman, and I. Vergote, “Clinical management of uterine sarcomas,” The Lancet Oncology, vol. 10, no. 12, pp. 1188–1198, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. R. L. Giuntoli II, E. Garrett-Mayer, R. E. Bristow, and B. S. Gostout, “Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma,” Gynecologic Oncology, vol. 106, no. 1, pp. 82–88, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. S. George, Y. Feng, J. Manola et al., “Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors,” Cancer, vol. 120, no. 5, pp. 738–743, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. V. H. C. Bramwell, “Pazopanib and the treatment palette for soft-tissue sarcoma,” The Lancet, vol. 379, no. 9829, pp. 1854–1856, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. M. van Glabbeke, J. Verweij, I. Judson, and O. S. Nielsen, “Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas,” European Journal of Cancer, vol. 38, no. 4, pp. 543–549, 2002. View at Google Scholar · View at Scopus
  83. S. M. Schuetze, “Imaging and response in soft tissue sarcomas,” Hematology/Oncology Clinics of North America, vol. 19, no. 3, pp. 471–487, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Verweij, “Soft tissue sarcoma trials: one size no longer fits all,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3085–3087, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. R. S. Benjamin, H. Choi, H. A. Macapinlac et al., “We should desist using RECIST, at least in GIST,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1760–1764, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Choi, C. Charnsangavej, S. C. Faria et al., “Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1753–1759, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. M. J. Payne, R. E. Macpherson, K. M. Bradley, and A. B. Hassan, “Trabectedin in advanced high-grade uterine leiomyosarcoma: a case report illustrating the value of 18FDG-PET-CT in assessing treatment response,” Case Reports in Oncology, vol. 7, no. 1, pp. 132–138, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. B. Kasper, T. Schmitt, P. Wuchter, A. Dimitrakopoulou-Strauss, A. D. Ho, and G. Egerer, “The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin,” Marine Drugs, vol. 7, no. 3, pp. 331–340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. J. Verweij, “Other endpoints in screening studies for soft tissue sarcomas,” Oncologist, vol. 13, no. 2, pp. 27–31, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Hollebecque, A. Adenis, S. Taieb, C. Lebedinsky, and N. Penel, “Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients,” Investigational New Drugs, vol. 28, no. 4, pp. 529–530, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Turpin, S. Taieb, and N. Penel, “Tumor calcification: a new response pattern of myxoid liposarcoma to trabectedin,” Case Reports in Oncology, vol. 7, no. 1, pp. 204–209, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. M. D'Incalci and C. M. Galmarini, “A review of trabectedin (ET-743): a unique mechanism of action,” Molecular Cancer Therapeutics, vol. 9, no. 8, pp. 2157–2163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. P. Schoffski, P. Casali, M. Taron et al., “DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743),” Journal of Clinical Oncology, vol. 24, supplement 18, p. 9522, 2006. View at Google Scholar
  94. A. B. Herrero, C. Martín-Castellanos, E. Marco, F. Gago, and S. Moreno, “Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin,” Cancer Research, vol. 66, no. 16, pp. 8155–8162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Tavecchio, M. Simone, E. Erba et al., “Role of homologous recombination in trabectedin-induced DNA damage,” European Journal of Cancer, vol. 44, no. 4, pp. 609–618, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. Y. Takebayashi, P. Pourquier, D. B. Zimonjic et al., “Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair,” Nature Medicine, vol. 7, no. 8, pp. 961–966, 2001. View at Google Scholar
  97. G. Damia, S. Silvestri, L. Carrassa et al., “Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways,” International Journal of Cancer, vol. 92, no. 4, pp. 583–588, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. P. Allavena, M. Signorelli, M. Chieppa et al., “Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production,” Cancer Research, vol. 65, no. 7, pp. 2964–2971, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. G. Germano, R. Frapolli, M. Simone et al., “Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells,” Cancer Research, vol. 70, no. 6, pp. 2235–2244, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. G. Germano, R. Frapolli, C. Belgiovine et al., “Role of macrophage targeting in the antitumor activity of trabectedin,” Cancer Cell, vol. 23, no. 2, pp. 249–262, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. G. Germano, A. Mantovani, and P. Allavena, “Targeting of the innate immunity/inflammation as complementary anti-tumor therapies,” Annals of Medicine, vol. 43, no. 8, pp. 581–593, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. R. Dossi, R. Frapolli, S. Di Giandomenico et al., “Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1,” International Journal of Cancer, vol. 136, no. 3, pp. 721–729, 2015. View at Publisher · View at Google Scholar
  103. F. Grosso, G. D. Demetri, J. Y. Blay et al., “Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas,” Journal of Clinical Oncology, vol. 24, no. 18, supplement 9511, 2006. View at Google Scholar
  104. F. Grosso, R. L. Jones, G. D. Demetri et al., “Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study,” The Lancet Oncology, vol. 8, no. 7, pp. 595–602, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. European Medicines Agency (EMA), Yondelis; Trabectedin, 2010, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000773/human_med_001165.jsp&murl=menus/medicines/medicines.jsp&jsenabled=true.
  106. P. G. Casali, R. Sanfilippo, and M. D'Incalci, “Trabectedin therapy for sarcomas,” Current Opinion in Oncology, vol. 22, no. 4, pp. 342–346, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. J.-Y. Blay, A. Italiano, I. Ray-Coquard et al., “Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program,” BMC Cancer, vol. 13, no. 1, article 64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Le Cesne, I. Ray-Coquard, F. Duffaud et al., “A large retrospective analysis of trabectedin in 885 patients with advanced soft tissue sarcoma,” Journal of Clinical Oncology, vol. 31, supplement, abstract 10563, 2013. View at Google Scholar
  109. A. le Cesne, J. Blay, T. Ryckewaert et al., “Benefit of maintenance therapy with trabectedin (T) beyond the 6 first cycles: results of a prospective randomized phase II trial comparing interruption vs. continuation of T in patients (pts) with advanced soft tissue sarcoma (ASTS): an update,” Annals of Oncology, vol. 25, supplement 4, Abstract 1414O, 2014. View at Google Scholar
  110. A. le Cesne, A. Yovine, J.-Y. Blay et al., “A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials,” Investigational New Drugs, vol. 30, no. 3, pp. 1193–1202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. L. Paz-Ares, A. López-Pousa, A. Poveda et al., “Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone,” Investigational New Drugs, vol. 30, no. 2, pp. 729–740, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. N. J. Carter and S. J. Keam, “Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer,” Drugs, vol. 70, no. 3, pp. 355–376, 2010. View at Google Scholar · View at Scopus
  113. P. Schöffski, P. Wolter, P. Clement et al., “Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma,” Future Oncology, vol. 3, no. 4, pp. 381–392, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. A. L. A. Ferreira, L. S. Matsubara, and B. B. Matsubara, “Anthracycline-induced cardiotoxicity,” Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 6, no. 4, pp. 278–281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. A. Le Cesne, E. Antoine, M. Spielmann et al., “High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas,” Journal of Clinical Oncology, vol. 13, no. 7, pp. 1600–1608, 1995. View at Google Scholar · View at Scopus
  116. J.-Y. Blay, M. Von Mehren, B. L. Samuels et al., “Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma,” Clinical Cancer Research, vol. 14, no. 20, pp. 6656–6662, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. C. Sessa, A. Perotti, C. Noberasco et al., “Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer,” European Journal of Cancer, vol. 45, no. 7, pp. 1153–1161, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. A. Gadducci and M. E. Guerrieri, “Pharmacological treatment for uterine leiomyosarcomas,” Expert Opinion on Pharmacotherapy, vol. 16, no. 3, pp. 335–346, 2015. View at Publisher · View at Google Scholar